1.Mechanism of tigecycline resistance induced in vitro in Citrobacter freundii
Hang MU ; Hao FU ; Jie ZHOU ; Shubo WANG ; Jingyuan ZHANG ; Ledi MA ; Jin ZHANG ; Shuyong WEI
Chinese Journal of Veterinary Science 2025;45(10):2222-2230
Tigecycline(TGC)is a recently developed broad-spectrum and highly effective glycylcy-cline antibiotic that overcomes traditional tetracycline resistance mechanisms.It is widely used in the treatment of complex skin and intra-abdominal infections.However,the emergence of TGC re-sistance in recent years poses a significant challenge,and its underlying resistance mechanisms re-main incompletely understood,warranting further investigation.This study induced TGC resistance in Klebsiella aerogenes(ATCC-43864)under in vitro conditions and evaluated phenotypic chan-ges,including growth curves,motility,multidrug susceptibility,and ultrastructural alterations,be-fore and after induction.Whole-genome sequencing(WGS)and transcriptome sequencing(RNA-seq)were employed to analyze resistance-related genetic changes,which were further validated.Ef-flux pump inhibition assays and Red homologous recombination were used to investigate the roles of efflux pumps,lon deletion,and rpsM mutation in TGC resistance.A stable resistant strain,CF-T-32,was obtained,with a 32-fold increase in TGC minimum inhibitory concentration(MIC).CF-T-32 exhibited an enlarged periplasmic space between the cell wall and membrane,reduced growth and motility,and no significant changes in susceptibility to 28 antimicrobial agents,including doxy-cycline,gentamicin,and ciprofloxacin.Genomic analysis revealed no significant differences in ge-nome composition or interference from exogenous plasmids between the parental and induced strains.However,two missense mutations were identified in rpsM and lon.Transcriptomic analysis and qPCR validation showed significant upregulation of efflux pump genes(acrA and acrB)in the AcrAB-TolC system and downregulation of ribosomal protein genes(rpsM,rpsJ,and rpsC).Ef-flux pump inhibition and Red homologous recombination experiments demonstrated that the rpsM C287T missense mutation,leading to a Pro96Leu substitution and reduced expression,is likely the primary factor contributing to TGC resistance in the induced strain.
2.Development and validation of a prediction score for subtype diagnosis of primary aldosteronism.
Ping LIU ; Wei ZHANG ; Jiao WANG ; Hongfei JI ; Haibin WANG ; Lin ZHAO ; Jinbo HU ; Hang SHEN ; Yi LI ; Chunhua SONG ; Feng GUO ; Xiaojun MA ; Qingzhu WANG ; Zhankui JIA ; Xuepei ZHANG ; Mingwei SHAO ; Yi SONG ; Xunjie FAN ; Yuanyuan LUO ; Fangyi WEI ; Xiaotong WANG ; Yanyan ZHAO ; Guijun QIN
Chinese Medical Journal 2025;138(23):3206-3208
3.Application effect of visual eye dressings in patients after bilateral strabismus surgery
Wei SONG ; Ying SHA ; Hang YIN ; Zhangfang MA
Chinese Journal of Modern Nursing 2025;31(17):2335-2337
Objective:To explore the application effect of visual eye dressings in patients after bilateral strabismus surgery.Methods:A total of 60 patients who underwent bilateral strabismus surgery in the Department of Ophthalmology of Beijing Tongren Hospital, Capital Medical University, from March to August 2024, were selected by convenience sampling. The patients were randomly divided into an observation group and a control group using a random number table method, with 30 cases in each group. After surgery, the control group was treated with conventional eye dressings, while the observation group was treated with visual eye dressings. The daily living ability, unplanned dressing changes were compared between the two groups.Results:The observation group had higher daily living ability scores and fewer unplanned dressing changes than the control group, and the differences were statistically significant ( P<0.05) . Conclusions:The use of visual eye dressings in patients after bilateral strabismus surgery has a positive effect on maintaining daily living ability and reducing the frequency of unplanned dressing changes.
4.Non-pharmacological interventions in chronic prostatitis/chronic pelvic pain syndrome:A network meta-analysis
Xiao-hui WEI ; Meng-yao MA ; Hang SU ; Tong HU ; Yu-xin ZHAO ; Xing-chao LIU ; Hong-yan BI
National Journal of Andrology 2025;31(3):234-245
Objective:To evaluate the efficacy of shockwave therapy,acupuncture,hyperthermia,biofeedback therapy,elec-trical nerve stimulation,magnetotherapy and ultrasound therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome(CP/CPPS),and to provide evidence-based support for clinical decision-making.Methods:Two researchers independently searched PubMed,Web of Science,Embase,Cochrane Library,CNKI,Wanfang,VIP and Chinese Biomedical Literature databases for randomized controlled trials(RCTs)on the effects of different interventions on CP/CPPS from the establishment of the databases to August 2024.We evaluated the quality of the included literature and extracted the relevant data according to the Cochrane Handbook for Systematic Reviews of Interventions,followed by network meta-analysis using Revman 5.3,R 4.33 and Stata17 software.Results:A total of 25 RCTs involving 1 794 cases were included.The results of network meta-analysis showed that electrical nerve stimulation,shockwave therapy,biofeedback therapy,magnetotherapy,ultrasound therapy and acupuncture were significantly superior to conventional medication and placebo in the total NIH-CPSI scores(P<0.05),and so were electrical nerve stimulation and shock-wave therapy to acupuncture and hyperthermia(P<0.05),magnetic therapy to hyperthermia,and ultrasound therapy to placebo(P<0.05).Shockwave therapy,biofeedback therapy,electrical nerve stimulation,magnetotherapy and ultrasound therapy achieved re-markably better clinical efficacy than conventional medication and placebo in the treatment of CP/CPPS,and so did shockwave therapy than electrical nerve stimulation,hyperthermia,ultrasonic therapy,magnetotherapy and acupuncture.Conclusion:For the treat-ment of CP/CPPS,electrical nerve stimulation is advantageous over the other interventions in improving total NIH-CPSI scores,and shockwave therapy is advantageous in relieving pain symptoms and clinical efficacy.This conclusion,however,needs to be further veri-fied by more high-quality clinical studies.
5.Mechanism of tigecycline resistance induced in vitro in Citrobacter freundii
Hang MU ; Hao FU ; Jie ZHOU ; Shubo WANG ; Jingyuan ZHANG ; Ledi MA ; Jin ZHANG ; Shuyong WEI
Chinese Journal of Veterinary Science 2025;45(10):2222-2230
Tigecycline(TGC)is a recently developed broad-spectrum and highly effective glycylcy-cline antibiotic that overcomes traditional tetracycline resistance mechanisms.It is widely used in the treatment of complex skin and intra-abdominal infections.However,the emergence of TGC re-sistance in recent years poses a significant challenge,and its underlying resistance mechanisms re-main incompletely understood,warranting further investigation.This study induced TGC resistance in Klebsiella aerogenes(ATCC-43864)under in vitro conditions and evaluated phenotypic chan-ges,including growth curves,motility,multidrug susceptibility,and ultrastructural alterations,be-fore and after induction.Whole-genome sequencing(WGS)and transcriptome sequencing(RNA-seq)were employed to analyze resistance-related genetic changes,which were further validated.Ef-flux pump inhibition assays and Red homologous recombination were used to investigate the roles of efflux pumps,lon deletion,and rpsM mutation in TGC resistance.A stable resistant strain,CF-T-32,was obtained,with a 32-fold increase in TGC minimum inhibitory concentration(MIC).CF-T-32 exhibited an enlarged periplasmic space between the cell wall and membrane,reduced growth and motility,and no significant changes in susceptibility to 28 antimicrobial agents,including doxy-cycline,gentamicin,and ciprofloxacin.Genomic analysis revealed no significant differences in ge-nome composition or interference from exogenous plasmids between the parental and induced strains.However,two missense mutations were identified in rpsM and lon.Transcriptomic analysis and qPCR validation showed significant upregulation of efflux pump genes(acrA and acrB)in the AcrAB-TolC system and downregulation of ribosomal protein genes(rpsM,rpsJ,and rpsC).Ef-flux pump inhibition and Red homologous recombination experiments demonstrated that the rpsM C287T missense mutation,leading to a Pro96Leu substitution and reduced expression,is likely the primary factor contributing to TGC resistance in the induced strain.
6.Application effect of visual eye dressings in patients after bilateral strabismus surgery
Wei SONG ; Ying SHA ; Hang YIN ; Zhangfang MA
Chinese Journal of Modern Nursing 2025;31(17):2335-2337
Objective:To explore the application effect of visual eye dressings in patients after bilateral strabismus surgery.Methods:A total of 60 patients who underwent bilateral strabismus surgery in the Department of Ophthalmology of Beijing Tongren Hospital, Capital Medical University, from March to August 2024, were selected by convenience sampling. The patients were randomly divided into an observation group and a control group using a random number table method, with 30 cases in each group. After surgery, the control group was treated with conventional eye dressings, while the observation group was treated with visual eye dressings. The daily living ability, unplanned dressing changes were compared between the two groups.Results:The observation group had higher daily living ability scores and fewer unplanned dressing changes than the control group, and the differences were statistically significant ( P<0.05) . Conclusions:The use of visual eye dressings in patients after bilateral strabismus surgery has a positive effect on maintaining daily living ability and reducing the frequency of unplanned dressing changes.
7.Risk Factor Analysis of Mitral Valve Repair Failure Based on Machine Learning
Xiaolin DIAO ; Kun ZHU ; Yun XIA ; Hang XU ; Shanshan ZHENG ; Jiexu MA ; Zhan YANG ; Zhaohong SUN ; Sheng LIU ; Wei ZHAO
Chinese Circulation Journal 2024;39(12):1190-1198
Objectives:To develop a novel prediction model for mitral valve repair failure based on machine learning algorithms.Methods:Clinical and echocardiographic data were analyzed on patients,who underwent mitral valve repair in Fuwai Hospital from 2009 January 1st to 2022 December 31st.End points included immediate mitral valve repair failure (mitral replacement secondary to mitral repair failure) and recurrence regurgitation (moderate or severe mitral regurgitation before discharge).Risk factors of mitral valve repair failure were analyzed by XGBoost and shapley additive explanation (SHAP),and a machine learning model was established based on mixture of experts (MoE) as a risk prediction model and compared with conventional mitral valve repair complexity scores.Results:A total of 2314 patients were included in this study.Mitral repair was unsuccessful in 4.2% (98 of 2314) of patients.Patient factors such as tricuspid regurgitation pressure gradient,A3 and A3P3 lesions,left ventricular end-systolic volume,and left atrium anterior and posterior diameter are associated with mitral valve repair failure;in addition,surgeon factors,such as cumulative repair failure rate,cumulative repair volume,and surgeon seniority,are also risk factors for mitral valve repair failure.The MoE model has an AUC value of 0.79,and the prediction performance is significantly better than traditional complexity scores.Conclusions:The MoE based machine learning model can predict the risk of mitral valve repair failure well.This evaluation system can effectively assist surgeons in assessing the risk of mitral valve repair failure and in selecting suitable treatment options for patients.
8.Enhancement of tropane alkaloids biosynthesis in Atropa belladonna hariy root by overexpression of HnCYP82M3 and DsTRI genes
De-hui MU ; Yan-hong LIU ; Piao-piao CHEN ; Ai-juan TAN ; Bing-nan MA ; Hang PAN ; Ming-sheng ZHANG ; Wei QIANG
Acta Pharmaceutica Sinica 2024;59(3):775-783
Tropane alkaloids (TAs) are a class of anticholinergic drugs widely used in clinical practice and mainly extracted from plant, among which
9.Progress in research on diseases related to patent foramen ovale in 2023
Lin QIU ; Hang ZHU ; Wei MA ; Yu-Shun ZHANG
Chinese Journal of Interventional Cardiology 2024;32(1):9-13
Patent foramen ovale(PFO)is a congenital heart disease with a relatively high prevalence in the population.Past studies have clarified its association with strokes and recognized the significance of PFO closure for PFO-related strokes.In recent years,research on diseases related to PFO has gradually increased and deepened our understanding.Meanwhile,the number of closure treatments for PFO in China has also significantly increased.This article reviews the latest research progress in the PFO field for the year 2023,mainly including the expansion of the spectrum of PFO-related diseases(such as epilepsy,unexplained syncope,etc.),exploration of the mechanisms of disease,and means of risk assessment.Regarding PFO closure treatment,this article introduces the latest research results concerning the effects of closure and prognosis,as well as the relationship between closure treatment and atrial fibrillation.China has always been in a leading position in the development of new devices for PFO closure,and this article also introduces the latest achievements in this area.
10.Clinical features of hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cell carcinoma: a multi-center real-world retrospective study
Yunze XU ; Wen KONG ; Ming CAO ; Guangxi SUN ; Jinge ZHAO ; Songyang LIU ; Zhiling ZHANG ; Liru HE ; Xiaoqun YANG ; Haizhou ZHANG ; Lieyu XU ; Yanfei YU ; Hang WANG ; Honggang QI ; Tianyuan XU ; Bo YANG ; Yichu YUAN ; Dongning CHEN ; Dengqiang LIN ; Fangjian ZHOU ; Qiang WEI ; Wei XUE ; Xin MA ; Pei DONG ; Hao ZENG ; Jin ZHANG
Chinese Journal of Urology 2024;45(3):161-167
Objective:To investigate the clinical features and therapeutic efficacy of patients with hereditary leiomyomatosis and renal cell carcinoma(RCC) syndrome-associated RCC (HLRCC-RCC) in China.Methods:The clinical data of 119 HLRCC-RCC patients with fumarate hydratase (FH) germline mutation confirmed by genetic diagnosis from 15 medical centers nationwide from January 2008 to December 2021 were retrospectively analyzed. Among them, 73 were male and 46 were female. The median age was 38(13, 74) years. The median tumor diameter was 6.5 (1.0, 20.5) cm. There were 38 cases (31.9%) in stage Ⅰ-Ⅱand 81 cases (68.1%) in stage Ⅲ-Ⅳ. In this group, only 11 of 119 HLRCC-RCC patients presented with skin smooth muscle tumors, and 44 of 46 female HLRCC-RCC patients had a history of uterine fibroids. The pathological characteristics, treatment methods, prognosis and survival of the patients were summarized.Results:A total of 86 patients underwent surgical treatment, including 70 cases of radical nephrectomy, 5 cases of partial nephrectomy, and 11 cases of reductive nephrectomy. The other 33 patients with newly diagnosed metastasis underwent renal puncture biopsy. The results of genetic testing showed that 94 patients had FH gene point mutation, 18 had FH gene insertion/deletion mutation, 4 had FH gene splicing mutation, 2 had FH gene large fragment deletion and 1 had FH gene copy number mutation. Immunohistochemical staining showed strong 2-succinocysteine (2-SC) positive and FH negative in 113 patients. A total of 102 patients received systematic treatment, including 44 newly diagnosed patients with metastasis and 58 patients with postoperative metastasis. Among them, 33 patients were treated with tyrosine kinase inhibitor (TKI) combined with immune checkpoint inhibitor (ICI), 8 patients were treated with bevacizumab combined with erlotinib, and 61 patients were treated with TKI monotherapy. Survival analysis showed that the median progression-free survival (PFS) of TKI combined with ICI was 18 (5, 38) months, and the median overall survival (OS) was not reached. The median PFS and OS were 12 (5, 14) months and 30 (10, 32) months in the bevacizumab combined with erlotinib treatment group, respectively. The median PFS and OS were 10 (3, 64) months and 44 (10, 74) months in the TKI monotherapy group, respectively. PFS ( P=0.009) and OS ( P=0.006) in TKI combined with ICI group were better than those in bevacizumab combined with erlotinib group. The median PFS ( P=0.003) and median OS ( P=0.028) in TKI combined with ICI group were better than those in TKI monotherapy group. Conclusions:HLRCC-RCC is rare but has a high degree of malignancy, poor prognosis and familial genetic characteristics. Immunohistochemical staining with strong positive 2-SC and negative FH can provide an important basis for clinical diagnosis. Genetic detection of FH gene germ line mutation can confirm the diagnosis. The preliminary study results confirmed that TKI combined with ICI had a good clinical effect, but it needs to be confirmed by the results of a large sample multi-center randomized controlled clinical study.

Result Analysis
Print
Save
E-mail